Xencor Inc (XNCR)

Xencor Announces Change to Ultomiris® Royalty Revenue ForecastMarch 4, 2026 4:01 PM
Business Wire
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any future payments for sales in the United States. The Licensee informed the Company that it intends to continue making royalty payments for sales of Ultomiris outside the United States.


“Xencor has reasonably assumed that the multiple licensees of our XmAb Fc domains and technologies remit payments in accordance with the terms of their respective agreements. One licensee has expressed disagreement regarding payments for net sales of Ultomiris in the United States, and we plan to work toward a resolution in this matter. Importantly, we have not observed a change in payments related to ex-U.S. sales,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. “We have updated our year-end cash guidance and conservatively adjust our operating runway estimate into mid-2028.”


The Company previously announced the issuance of U.S. Patent 12,492,253 and its expectation to receive an estimated additional $100 to $120 million in aggregate through 2028 in low single-digit royalties on net sales of Ultomiris in the United States from the Licensee. Ultomiris is a drug being developed and commercialized by the Licensee and is a registered trademark of the Licensee.


Financial Guidance: Based on current operating plans, Xencor expects to end 2026 with between $380 million and $400 million in cash, cash equivalents and marketable debt securities, and to have sufficient cash resources to fund research and development programs and operations into mid-2028.


About Xencor


Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.


Forward-Looking Statements


Certain statements contained in this press release may constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are not purely statements of historical fact, and can generally be identified by the use of words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “indicates,” “supports,” and similar terms, or by express or implied discussions relating to Xencor’s business, including, but not limited to, statements regarding projected financial resources and financial guidance, including estimated cash, cash equivalents and marketable debt securities at year end and cash runway for research and development programs and operations, expectations for and estimates of future royalty revenues, the quotations from Xencor's president and chief executive officer, and other statements that are not purely statements of historical fact. Such statements are made on the basis of the current beliefs, expectations, and assumptions of the management of Xencor and are subject to significant known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements and the timing of events to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such risks include, without limitation, the risks associated with the process of discovering, developing, manufacturing and commercializing drugs that are safe and effective for use as human therapeutics, the ability of publicly disclosed preliminary clinical trial data to support continued clinical development and regulatory approval for specific treatments, the risk of loss of key members of management, the risk that the fair value of our marketable equity securities will decline and the risks, uncertainties and other factors described under the heading “Risk Factors” in Xencor's Annual Report on Form 10-K for the year ended December 31, 2025 as well as Xencor's subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Xencor undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260304935463/en/
For Investors:

Charles Liles

cliles@xencor.com

(626) 737-8118


For Media:

Cassidy McClain

Inizio Evoke

cassidy.mcclain@inizioevoke.com

(619) 694-6291


Original: Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

XNCR over $20

$XNCR recent news/filings

bullish

## source: finance.yahoo.com

Fri, 12 Jun 2015 12:00:00 GMT ~ Xencor to Host R&D Day and Webcast on June 26, 2015

[PR Newswire] - MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...

read full: http://finance.yahoo.com/news/xencor-host-r-d-day-120000081.html
*********************************************************

Thu, 11 Jun 2015 20:17:48 GMT ~ XENCOR INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150611/xncr8-k.html
*********************************************************

Wed, 10 Jun 2015 12:32:02 GMT ~ Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

[at noodls] - MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, ...

read full: http://www.noodls.com/view/AA266D2A7FC4D8DB24C959D4C795C13E54201814
*********************************************************

Wed, 10 Jun 2015 12:01:19 GMT ~ XENCOR INC Files SEC form 8-K, Other Events


read full: http://biz.yahoo.com/e/150610/xncr8-k.html
*********************************************************

Wed, 10 Jun 2015 12:00:00 GMT ~ Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

[PR Newswire] - MONROVIA, Calif., June 10, 2015 /PRNewswire/ -- Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported complete data results from a Phase 1b/2a study of XmAb®5871 in patients with rheumatoid arthritis (RA). XmAb5871 was generally well tolerated and showed trends in improvement in RA disease activity by multiple disease activity measures and across multiple dose groups. "These data demonstrate clear signs of disease modifying activity in a patient population with active disease while on non-biologic disease modifying anti-rheumatic drug (DMARD) therapy," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor.

read full: http://finance.yahoo.com/news/xencor-reports-complete-data-results-120000838.html
*********************************************************

$XNCR charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$XNCR company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/XNCR/company-info
Ticker: $XNCR
OTC Market Place: Not Available
CIK code: not found
Company name: Xencor, Inc.
Incorporated In:



$XNCR share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$XNCR extra dd links

Company name: Xencor, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=XNCR+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=XNCR+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=XNCR+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/news - http://finance.yahoo.com/q/h?s=XNCR+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/XNCR/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=XNCR+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/XNCR
DTCC (dtcc.com): http://search2.dtcc.com/?q=Xencor%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Xencor%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Xencor%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/XNCR
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=XNCR&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=XNCR
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=XNCR+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=XNCR+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=XNCR
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=XNCR
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=XNCR+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/XNCR/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=XNCR+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/XNCR.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=XNCR
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/XNCR/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/XNCR/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/XNCR
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/XNCR
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/XNCR:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=XNCR
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=XNCR



$XNCR DD Notes ~ http://www.ddnotesmaker.com/XNCR

XmAb7195 Questions

1. XmAb7195 engages the Fc?RIIb on B-cells to dampen IgE production. Bassil said it would take months to see an effect. Why does it take long? Shouldn't the B-cell be shut down immediately?

2. XmAb7195 engages the Fc?RIIb on liver sinusoidal endothelial cells, targeting IgE bound XmAb7195 to the liver for destruction, which was shown nicely by PET imaging in mice. IgG1 is a nice control, but it is not Xolair, like Bassil eluded to, it does not bind IgE. Bassil stated Xolair does not go to the liver, but I don't see any evidence of that, where is the data?

I know right! From over 10 to under 8. Should rise back up though since no news have been published.

Wow, what a dump, way to go management.

Bring in some good news, quit being in the dark.

Translation to all fields of medicine

biologic therapies are already huge money makers. they are used in certain breast cancers, rheumatoid arthritis, ankylosing spondylitis, crohn's disease, certain lymphomas, etc. Imagine improving each of the current therapies for all of these conditions. at the very least, Xencor Inc could lease engineered Fc-fragment patents to each of these companies to improve their current therapy.

i see XNCR reaching ~$13-16 before any results are published. and depending on the results of current trials, this company could be worth billions.

Thanks, same 2u.

Meryy christmas to all and a hopeful 2014.

DumpsterDiver, I believe so.

What are the odds that this thing doubles after the clinicals after the new year.

Non-hodgekins lymphoma, asthma, and lupous are pretty good starting blocks for cures, dont ya think.

Dang, guess I got stuck with 3rd. Lets go clinical trials!

Oh yeah!! Second!

New board.